Durability of Response to B‐Cell Maturation Antigen‐Directed <scp>mRNA</scp> Cell Therapy in Myasthenia Gravis
These data support continued development of Descartes-08 in myasthenia gravis and other autoantibody-associated autoimmune disorders.
Authors
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Charles A. Stewart (ORCID: https://orcid.org/0000-0001-7936-447X)
- Nizar Chahin
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Metin Kurtoğlu
- Marc H. Feinberg
- Gregory Sahagian
- Christopher M. Jewell (ORCID: https://orcid.org/0000-0002-6668-6928)
- Miloš D. Miljković (ORCID: https://orcid.org/0000-0001-5848-6320)
- Tahseen Mozaffar (ORCID: https://orcid.org/0000-0002-1230-0188)
Institutions
- University of North Carolina at Chapel Hill (US)
- Oregon Health & Science University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- Boca Raton Regional Hospital (US)
- Neurology Center of Southern California (US)
- Cara Therapeutics (United States) (US)
- Southern States University (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1002/acn3.70167
- Citations
- 7
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke